Vistacom, Barco and Winsted Experts Discuss Critical Role of Control Room Operators

ALLENTOWN, PA – The latest episode of Tech Unraveled by Vistacom focuses on the critical role of control room operators in the utility and energy industries. Hosts Joshua Herring and Lianna Russell are joined by Lee Pagnan, National Sales Manager of Utilities at Barco, and Shawn Brady, VP of Product Development at Winsted, who bring their extensive knowledge and expertise to the discussion.

 

Control room operators are responsible for managing various aspects of the energy and utility industries, including surveillance, command and control, traffic management, and broadcasting distribution monitoring. The podcast covers the daily tasks of control mission operators, the importance of ergonomic resolutions for operation work centers, and commonly overlooked design considerations.

 

Brady highlights the difference between task data and viewable data and explains how operators want access to both. However, moving viewable data to a display wall while keeping task data on the desk can lead to greater efficiency. Pagnan shares his thoughts on the trend of increased preparedness of control centers and the need for additional control centers in the wake of the COVID-19 pandemic.

 

Tech Unraveled by Vistacom explores the latest technology trends and their impact on various industries. Tune in to the latest episode to learn more about the critical role of control room operators in the utility and energy industries.

 

 

 

About Barco:

Barco is a technology company that specializes in visualization and collaboration solutions for various industries, including utilities and energy.

 

About Winsted:

Winsted is a provider of control room furniture solutions for mission critical industries, including utilities and energy. Their products are designed to meet the specific needs of control room operators and to enhance their productivity and comfort.

 

About Vistacom:
Vistacom is a leading family-owned audiovisual integration firm established in 1954. Known for exceptional customer service, quality workmanship and innovative solutions, Vistacom is now one of the top 50 AV firms globally.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More